Physician profile
Mary E Prevost
NPI 1306975974
$12,472.17
in general payments reported to CMS, 2019-2025
51 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,875 · 2022: $2,244 · 2023: $3,367 · 2024: $2,702 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,353.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,058.90 | 2021-2025 | Otezla, Tavneos, Otezla |
| Abbvie INC. | $1,987.91 | 2021-2025 | |
| Ucb, INC. | $1,014.71 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $853.99 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $766.41 | 2021-2025 | Acthar |
| Novo Nordisk INC | $614.50 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $607.40 | 2021-2025 | Ofev, Jardiance, Synjardy |
| Preventric Diagnostics, INC. | $595.92 | 2022 | |
| Glaxosmithkline, LLC. | $545.78 | 2021-2025 | Benlysta, Nucala, Shingrix |
| Janssen Biotech, INC. | $486.12 | 2021-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $281.48 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $214.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.22 | 2021-2024 | |
| Dexcom, INC. | $180.34 | 2022-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $173.62 | 2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Prevost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.